Core Concepts
Active surveillance is a viable option for managing non-muscle-invasive bladder tumors, improving patient quality of life.
Abstract
The content discusses the promotion of active surveillance for non-muscle-invasive bladder tumors (NMIBT) as a comprehensive management approach, similar to prostate and kidney cancers. Dr. Benjamin Pradère advocates for this approach, emphasizing the use of biomarkers to enhance its effectiveness. The article delves into the challenges of managing precancerous lesions like NMIBT and the importance of careful patient selection, proper information, and relevant follow-up.
Key Highlights:
NMIBTs constitute 70%-80% of diagnosed bladder tumors.
Low-grade Ta tumors require longer-term monitoring.
Risk stratification distinguishes low, intermediate, high, and very high-risk tumors.
Active surveillance is recommended for recurrent low-risk NMIBT.
Follow-up modalities include cystoscopy every 3 months.
Literature on the benefits of active surveillance in bladder tumors is limited.
Factors predicting recurrence and progression of tumors are identified.
Biomarkers like the ADXBladder test can aid in active surveillance.
The future of active surveillance involves better patient selection and enhanced modalities.
Stats
NMIBTs constitute 70%-80% of diagnosed bladder tumors.
Recurrence rate for low-grade tumors is 50%.
Progression to invasive tumors occurred in 0.8% of patients.
The median duration of active surveillance is 13 months.
The ADXBladder test on a urine sample can predict recurrence risk.
Quotes
"Implementing active surveillance is a safe, cost-effective option that improves the quality of life." - Dr. Benjamin Pradère
"We know that low-grade NMIBTs have no impact on survival." - Dr. Benjamin Pradère
"The use of biomarkers should change the game and encourage active surveillance in patients with small polyps." - Dr. Benjamin Pradère